Reversal of Experimental Pulmonary Hypertension by PDGF Inhibition

Overview

Journal J Clin Invest

Specialty General Medicine

Date 2005 Oct 4

PMID 16200212

Citations 381

Authors

Ralph Theo Schermuly

Eva Dony

Hossein Ardeschir Ghofrani

Soni Pullamsetti

Rajkumar Savai

Markus Roth

Akylbek Sydykov

Ying Ju Lai

Norbert Weissmann

Werner Seeger

Friedrich Grimminger

Affiliations

Soon will be listed here.

Abstract

Progression of pulmonary hypertension is associated with increased proliferation and migration of pulmonary vascular smooth muscle cells. PDGF is a potent mitogen and involved in this process. We now report that the PDGF receptor antagonist STI571 (imatinib) reversed advanced pulmonary vascular disease in 2 animal models of pulmonary hypertension. In rats with monocrotaline-induced pulmonary hypertension, therapy with daily administration of STI571 was started 28 days after induction of the disease. A 2-week treatment resulted in 100% survival, compared with only 50% in sham-treated rats. The changes in RV pressure, measured continuously by telemetry, and right heart hypertrophy were reversed to near-normal levels. STI571 prevented phosphorylation of the PDGF receptor and suppressed activation of downstream signaling pathways. Similar results were obtained in chronically hypoxic mice, which were treated with STI571 after full establishment of pulmonary hypertension. Moreover, expression of the PDGF receptor was found to be significantly increased in lung tissue from pulmonary arterial hypertension patients compared with healthy donor lung tissue. We conclude that STI571 reverses vascular remodeling and cor pulmonale in severe experimental pulmonary hypertension regardless of the initiating stimulus. This regimen offers a unique novel approach for antire-modeling therapy in progressed pulmonary hypertension.

Citing Articles

Shear stress unveils patient-specific transcriptional signatures in PAH: Towards personalized molecular diagnostics.

Wittig C, Konig J, Pan X, Aman J, Bogaard H, Yu P Theranostics. 2025; 15(5):1589-1605.

PMID: 39897541 PMC: 11780538. DOI: 10.7150/thno.105729.

hUC-MSCs Prevent Acute High-Altitude Injury through Apoe/Pdgf-b/p-Erk1/2 Axis in Mice.

Yan S, Bi Y, Liu Q, Song S, Ma L, Ji G Stem Cell Rev Rep. 2025; .

PMID: 39871082 DOI: 10.1007/s12015-024-10840-1.

Impact of sodium-glucose cotransporter-2 inhibitors on pulmonary vascular cell function and arterial remodeling.

Zhang J, Ye X, Liu X, Zhang H, Qiao Q World J Cardiol. 2025; 17(1):101491.

PMID: 39866213 PMC: 11755123. DOI: 10.4330/wjc.v17.i1.101491.

Precision Medicine for Pulmonary Vascular Disease: The Future Is Now (2023 Grover Conference Series).

Forbes L, Bauer N, Bhadra A, Bogaard H, Choudhary G, Goss K Pulm Circ. 2025; 15(1):e70027.

PMID: 39749110 PMC: 11693987. DOI: 10.1002/pul2.70027.

NCAM1 modulates the proliferation and migration of pulmonary arterial smooth muscle cells in pulmonary hypertension.

Chen Y, Liu N, Yang Y, Yang L, Li Y, Qiao Z Respir Res. 2024; 25(1):435.

PMID: 39696429 PMC: 11657385. DOI: 10.1186/s12931-024-03068-7.

References

Cowan K, Heilbut A, Humpl T, Lam C, Ito S, Rabinovitch M . Complete reversal of fatal pulmonary hypertension in rats by a serine elastase inhibitor. Nat Med. 2000; 6(6):698-702. DOI: 10.1038/76282. View

Dagher R, Cohen M, Williams G, Rothmann M, Gobburu J, Robbie G . Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors. Clin Cancer Res. 2002; 8(10):3034-8. View

Buchdunger E, Cioffi C, Law N, Stover D, Druker B, Lydon N . Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther. 2000; 295(1):139-45. View

Eddahibi S, Humbert M, Sediame S, Chouaid C, Partovian C, Maitre B . Imbalance between platelet vascular endothelial growth factor and platelet-derived growth factor in pulmonary hypertension. Effect of prostacyclin therapy. Am J Respir Crit Care Med. 2000; 162(4 Pt 1):1493-9. DOI: 10.1164/ajrccm.162.4.2003124. View

Cho A, Graves J, Reidy M . Mitogen-activated protein kinases mediate matrix metalloproteinase-9 expression in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 2000; 20(12):2527-32. DOI: 10.1161/01.atv.20.12.2527. View

Tanabe Y, Saito M, Ueno A, Nakamura M, Takeishi K, Nakayama K . Mechanical stretch augments PDGF receptor beta expression and protein tyrosine phosphorylation in pulmonary artery tissue and smooth muscle cells. Mol Cell Biochem. 2001; 215(1-2):103-13. DOI: 10.1023/a:1026506801659. View

Chen E, Mazure N, Cooper J, Giaccia A . Hypoxia activates a platelet-derived growth factor receptor/phosphatidylinositol 3-kinase/Akt pathway that results in glycogen synthase kinase-3 inactivation. Cancer Res. 2001; 61(6):2429-33. View

Ushio-Fukai M, Griendling K, Becker P, Hilenski L, Halleran S, Alexander R . Epidermal growth factor receptor transactivation by angiotensin II requires reactive oxygen species in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 2001; 21(4):489-95. DOI: 10.1161/01.atv.21.4.489. View

Bergsten E, Uutela M, Li X, Pietras K, Ostman A, Heldin C . PDGF-D is a specific, protease-activated ligand for the PDGF beta-receptor. Nat Cell Biol. 2001; 3(5):512-6. DOI: 10.1038/35074588. View

10.

LaRochelle W, Jeffers M, McDonald W, Chillakuru R, Giese N, Lokker N . PDGF-D, a new protease-activated growth factor. Nat Cell Biol. 2001; 3(5):517-21. DOI: 10.1038/35074593. View

11.

Zhao L, Mason N, Morrell N, Kojonazarov B, Sadykov A, Maripov A . Sildenafil inhibits hypoxia-induced pulmonary hypertension. Circulation. 2001; 104(4):424-8. DOI: 10.1161/hc2901.093117. View

12.

Frisdal E, Gest V, Vieillard-Baron A, LEVAME M, Lepetit H, Eddahibi S . Gelatinase expression in pulmonary arteries during experimental pulmonary hypertension. Eur Respir J. 2002; 18(5):838-45. DOI: 10.1183/09031936.01.00084601. View

13.

Jeffery T, Wanstall J . Pulmonary vascular remodeling: a target for therapeutic intervention in pulmonary hypertension. Pharmacol Ther. 2001; 92(1):1-20. DOI: 10.1016/s0163-7258(01)00157-7. View

14.

Rubin L, Badesch D, Barst R, Galie N, Black C, Keogh A . Bosentan therapy for pulmonary arterial hypertension. N Engl J Med. 2002; 346(12):896-903. DOI: 10.1056/NEJMoa012212. View

15.

Ghofrani H, Wiedemann R, Rose F, Olschewski H, Schermuly R, Weissmann N . Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension. Ann Intern Med. 2002; 136(7):515-22. DOI: 10.7326/0003-4819-136-7-200204020-00008. View

16.

Cohen M, Williams G, Johnson J, Duan J, Gobburu J, Rahman A . Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. Clin Cancer Res. 2002; 8(5):935-42. View

17.

Wensel R, Opitz C, Anker S, Winkler J, Hoffken G, Kleber F . Assessment of survival in patients with primary pulmonary hypertension: importance of cardiopulmonary exercise testing. Circulation. 2002; 106(3):319-24. DOI: 10.1161/01.cir.0000022687.18568.2a. View

18.

Capdeville R, Buchdunger E, Zimmermann J, Matter A . Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat Rev Drug Discov. 2002; 1(7):493-502. DOI: 10.1038/nrd839. View

19.

Olschewski H, Simonneau G, Galie N, Higenbottam T, Naeije R, Rubin L . Inhaled iloprost for severe pulmonary hypertension. N Engl J Med. 2002; 347(5):322-9. DOI: 10.1056/NEJMoa020204. View

20.

Ghofrani H, Wiedemann R, Rose F, Schermuly R, Olschewski H, Weissmann N . Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. Lancet. 2002; 360(9337):895-900. DOI: 10.1016/S0140-6736(02)11024-5. View